Clinical Trial Update: Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating safety and efficacy of oral epeleuton in non-alcoholic fatty liver disease has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Epeleuton (Epeleuton)

Snippet

Sponsor: Afimmune | Conditions: Non Alcoholic Fatty Liver Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-04-21